Equities Analysts Set Expectations for MIRM Q3 Earnings

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) – Analysts at HC Wainwright cut their Q3 2025 EPS estimates for shares of Mirum Pharmaceuticals in a research report issued on Wednesday, November 13th. HC Wainwright analyst E. Arce now expects that the company will post earnings of $0.35 per share for the quarter, down from their prior forecast of $0.46. HC Wainwright currently has a “Buy” rating and a $66.00 target price on the stock. The consensus estimate for Mirum Pharmaceuticals’ current full-year earnings is ($1.84) per share. HC Wainwright also issued estimates for Mirum Pharmaceuticals’ Q4 2025 earnings at $0.61 EPS.

Mirum Pharmaceuticals (NASDAQ:MIRM) last posted its quarterly earnings data on Tuesday, November 12th. The company reported ($0.30) EPS for the quarter, beating analysts’ consensus estimates of ($0.45) by $0.15. Mirum Pharmaceuticals had a negative net margin of 31.69% and a negative return on equity of 40.98%. The company had revenue of $90.38 million for the quarter, compared to analyst estimates of $81.99 million. During the same period in the previous year, the business posted ($0.57) earnings per share. Mirum Pharmaceuticals’s quarterly revenue was up 89.4% on a year-over-year basis.

A number of other equities analysts have also recently weighed in on MIRM. Evercore ISI upped their price target on shares of Mirum Pharmaceuticals from $62.00 to $66.00 and gave the stock an “outperform” rating in a research note on Thursday, August 8th. Cantor Fitzgerald increased their price target on shares of Mirum Pharmaceuticals from $50.00 to $60.00 and gave the company an “overweight” rating in a research report on Thursday, August 8th. Robert W. Baird lifted their price objective on Mirum Pharmaceuticals from $44.00 to $50.00 and gave the stock an “outperform” rating in a research report on Wednesday. Citigroup raised their price target on Mirum Pharmaceuticals from $65.00 to $68.00 and gave the stock a “buy” rating in a research report on Wednesday. Finally, Leerink Partners upped their price objective on shares of Mirum Pharmaceuticals from $47.00 to $49.00 and gave the company an “outperform” rating in a research note on Thursday, October 17th. Ten investment analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat, Mirum Pharmaceuticals has a consensus rating of “Buy” and an average target price of $57.73.

Mirum Pharmaceuticals Stock Performance

Shares of MIRM stock opened at $43.92 on Thursday. Mirum Pharmaceuticals has a 52-week low of $23.14 and a 52-week high of $45.81. The stock’s 50-day moving average price is $39.96 and its 200 day moving average price is $35.79. The company has a quick ratio of 3.09, a current ratio of 3.28 and a debt-to-equity ratio of 1.34. The stock has a market capitalization of $2.10 billion, a PE ratio of -21.74 and a beta of 1.16.

Institutional Investors Weigh In On Mirum Pharmaceuticals

Several institutional investors have recently bought and sold shares of the business. Price T Rowe Associates Inc. MD boosted its position in shares of Mirum Pharmaceuticals by 37.2% in the first quarter. Price T Rowe Associates Inc. MD now owns 1,597,506 shares of the company’s stock worth $40,131,000 after buying an additional 432,824 shares during the period. Silvercrest Asset Management Group LLC lifted its holdings in Mirum Pharmaceuticals by 64.6% in the 1st quarter. Silvercrest Asset Management Group LLC now owns 162,817 shares of the company’s stock worth $4,090,000 after buying an additional 63,871 shares in the last quarter. Rice Hall James & Associates LLC boosted its holdings in Mirum Pharmaceuticals by 6.9% in the second quarter. Rice Hall James & Associates LLC now owns 229,730 shares of the company’s stock valued at $7,854,000 after purchasing an additional 14,843 shares during the last quarter. Candriam S.C.A. acquired a new stake in shares of Mirum Pharmaceuticals during the second quarter worth approximately $17,384,000. Finally, Hennion & Walsh Asset Management Inc. raised its stake in shares of Mirum Pharmaceuticals by 64.9% in the 2nd quarter. Hennion & Walsh Asset Management Inc. now owns 104,770 shares of the company’s stock valued at $3,582,000 after purchasing an additional 41,236 shares in the last quarter.

Mirum Pharmaceuticals Company Profile

Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.